Scientific Poster: Real-Time Live Cell Imaging in Successful ADC Development

07th December 2023

Introduction
Antibody Drug Conjugates (ADCs) are novel and emerging targeted therapeutics against cancer. ADCs deliver the specificity of mAb and cytotoxicity of small molecule drugs. In ADC Development, developability assessments underpin all aspects of ADC drug discovery, lead selection, and optimization.  Abzena uses real-time live cell imaging in the developability assessment of ADCs to select a lead drug candidate with the greatest chance of clinical success.

Poster authors include: Robert J. Francis , Natasha Carter, Grant Harradence, Robert Cunningham, Nathan Shaw, Adele Kinsey, Maryam Ahmadi, Erika Kovacs, Robert Holgate, Campbell Bunce

 

 

 

Summary
ADCs are novel therapeutics that deliver precision and efficacy in treatment of cancer. Understanding the mode of action, the antibody activity and the effectiveness of the cytotoxic drug, will allow the generation of new ADCs. The versatility that live cell imaging provides, either through the Incucyte or higher resolution spinning disk confocal microscopy, can be harnessed to capture the fundamental characteristics of successful drug design and increases the likelihood of obtaining a successful therapeutic candidate.

Abzena’s Bioassay Expertise

Abzena has decades of experience in developing bioassays for antibody drug conjugate (ADCs)  programs.  Our unique approach focuses on developing phase-appropriate assays for the assessment of potency, efficacy, and safety, to provide you with the tools to make effective decisions to ensure downstream clinical and commercial success.  We offer comprehensive bioassay solutions which include both established assays and custom assay development matched to your individual program needs. In discovery, we support our customers with target validation and hit-to-lead screening.  As you transition your program onwards towards design and developability, we can support you with specificity and tissue profiling, mode of action (MOAs) and immunogenicity assessments.  When it’s time to start manufacturing, we offer potency and batch release support.

For more information on our bioassay capabilities, click here.